Thankfully, we live in an increasingly digital data-driven world, notes Dr Gen Li (pictured), founder and CEO of Phesi.
The clinical development industry has more access to real-world data on rare diseases, patients and clinical trial designs than ever before — as well as advanced AI tools that can rapidly extract precise insights from this information.
Here we look at five challenges in rare disease clinical development and why sponsors should be taking a data-driven approach to address them.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.